A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.
John C. Byrd
Consultant or Advisory Role - Pharmacyclics (U)
Jacqueline Claudia Barrientos
Research Funding - Pharmacyclics
Stephen Devereux
No relevant relationships to disclose
Jennifer R. Brown
Consultant or Advisory Role - Avila Therapeutics; Celgene; Emergent BioSolutions; Genentech; Novartis; Pharmacyclics; Sanofi
Research Funding - Genzyme
Neil E. Kay
No relevant relationships to disclose
Nishitha M. Reddy
No relevant relationships to disclose
Susan Mary O'Brien
Research Funding - Pharmacyclics (B)
Thomas J. Kipps
Consultant or Advisory Role - Pharmacyclics (U)
Research Funding - Pharmacyclics
Richard R. Furman
Consultant or Advisory Role - Pharmacyclics (U)
Stephen J. Schuster
No relevant relationships to disclose
Adrian Bloor
No relevant relationships to disclose
Devinder Singh Gill
No relevant relationships to disclose
Patrick Thornton
No relevant relationships to disclose
Claire E. Dearden
No relevant relationships to disclose
Ulrich Jäger
No relevant relationships to disclose
Christine Barker
Employment or Leadership Position - Pharmacyclics
Jennifer Lin
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Lori A. Kunkel
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Peter Hillmen
Consultant or Advisory Role - Pharmacyclics (U)
Honoraria - Janssen Pharmaceutical
Expert Testimony - Pharmacyclics (U)